SALERNO PHARMS
PharmaSALERNO PHARMS is a pharmaceutical company focused on Cardiovascular, Metabolic. Key products include FLOLIPID.
SALERNO PHARMS's Key Drugs
SALERNO PHARMS's core commercial portfolio centers on FLOLIPID, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
SALERNO PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SALERNO PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SALERNO PHARMS's Therapeutic Areas
SALERNO PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SALERNO PHARMS's Top Competitors
SALERNO PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SALERNO PHARMS Pipeline Snapshot
Active clinical trials for SALERNO PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLOLIPID leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-04-21
- Latest
- 2020-09-25
- Applications
- 1